Shuttle Pharmaceuticals Has Been Granted A European Patent Titled DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION (FOR TREATMENT OF CANCERS, NEUROLOGICAL DISORDERS, & IMMUNOLOGICAL DISORDERS)